Entrada Therapeutics, Inc.
TRDA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001689375
In the last 90 days, Entrada Therapeutics, Inc. insiders filed 0 open-market purchases and 4 sales; 128 institutions reported holding it in 13F filings for Q2 2026, worth $214.4M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 8, 2026, 10:56 PM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $143.8M (565.5% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 8, 2026 | Jan 15, 2025 | Mar 13, 2024 | Mar 6, 2023 | Mar 15, 2022 |
| Revenue | $25.4M | $210.8M | $129.0M | – | – |
| Operating expenses | $183.3M | $163.8M | $132.2M | $97.2M | $51.1M |
| Research and development | $142.3M | $125.3M | $99.9M | $66.6M | $35.9M |
| Selling, general and administrative | $41.0M | $38.5M | $32.3M | $30.6M | $15.2M |
| Operating income | -$157.9M | $47.0M | -$3.16M | -$97.2M | -$51.1M |
| Income tax | $924.0K | $859.0K | $18.7M | $0 | $0 |
| Net income | -$143.8M | $65.6M | -$6.68M | -$94.6M | -$51.2M |
| EPS, basic | $-3.47 | $1.76 | $-0.20 | $-3.02 | $-8.16 |
| EPS, diluted | $-3.47 | $1.68 | $-0.20 | $-3.02 | $-8.16 |
| Weighted shares, basic | 41.4M | 37.3M | 33.1M | 31.3M | 6.27M |
| Weighted shares, diluted | 41.4M | 39.0M | 33.1M | 31.3M | 6.27M |
| Margins and growth | |||||
| Operating margin | -621.1% | 22.3% | -2.5% | – | – |
| Net margin | -565.5% | 31.1% | -5.2% | – | – |
| Revenue growth, year over year | −87.9% | +63.4% | – | – | – |
| Net income growth, year over year | −319.0% | – | – | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 8, 2026 | Jan 15, 2025 | Mar 13, 2024 | Mar 6, 2023 | Mar 15, 2022 |
| Cash and equivalents | $90.4M | $101.2M | $67.6M | $45.2M | $291.1M |
| Total current assets | $306.3M | $440.0M | $369.8M | $209.9M | $298.7M |
| Property, plant and equipment | $7.31M | $10.9M | $11.2M | $7.68M | $6.26M |
| Total assets | $377.4M | $526.3M | $469.2M | $252.1M | $305.8M |
| Accounts payable | $2.29M | $4.26M | $3.28M | $5.99M | $706.0K |
| Total current liabilities | $24.5M | $39.5M | $158.8M | $22.0M | $6.72M |
| Total liabilities | $71.2M | $97.6M | $226.8M | $39.5M | $7.12M |
| Shareholders' equity | $306.1M | $428.7M | $242.4M | $212.6M | $298.7M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 8, 2026 | Jan 15, 2025 | Mar 13, 2024 | Mar 6, 2023 | Mar 15, 2022 |
| Operating cash flow | -$128.5M | -$41.6M | $139.8M | -$93.8M | -$50.9M |
| Capital expenditures | $1.04M | $3.16M | $5.61M | $2.89M | $4.58M |
| Free cash flow | -$129.6M | -$44.7M | $134.2M | -$96.7M | -$55.4M |
| Stock-based compensation | $19.6M | $17.9M | $13.1M | $9.89M | $2.53M |
| Investing cash flow | $116.8M | -$27.8M | -$138.4M | -$148.7M | -$4.58M |
| Financing cash flow | $887.0K | $103.0M | $21.0M | $479.0K | $307.5M |
| Net change in cash | -$10.8M | $33.6M | $22.4M | -$242.0M | $252.0M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 77.1% | 8.5% | 10.2% | – | – |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 31, 2026 | 39.2M | +2.4% | SEC |
| Jul 31, 2026 | 38.9M | +2.4% | SEC |
| Apr 30, 2026 | 38.8M | +2.3% | SEC |
| Feb 19, 2026 | 38.3M | +1.8% | SEC |
| Oct 31, 2025 | 38.2M | +2.1% | SEC |
| Jul 31, 2025 | 38.0M | +2.3% | SEC |
| Apr 30, 2025 | 38.0M | +12.4% | SEC |
| Feb 20, 2025 | 37.6M | +11.9% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.